Provided by Tiger Trade Technology Pte. Ltd.

AKESO

105.000
-2.200-2.05%
Volume:7.76M
Turnover:808.42M
Market Cap:96.71B
PE:-85.17
High:106.000
Open:105.600
Low:102.200
Close:107.200
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.17
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.233
ROE:-13.59%
ROA:-4.49%
PB:9.72
PE(LYR):-85.17
PS:23.90

Loading ...

Akeso - to Place 20 Mln New Shares at Hk$97.76 Per Share

THOMSON REUTERS
·
33 mins ago

Movement Alert|AKESO Falls 3.45% in Regular Trading, Biotech Sector Pulls Back on Profit-Taking

Market Focus
·
Yesterday

Should Phase III Colon Cancer Trial Require Action From Akeso (SEHK:9926) Investors?

Simply Wall St.
·
Oct 12

Is Akeso (SEHK:9926) Cheap As Its Phase III Colon Cancer Trial Expands Its Pipeline?

Simply Wall St.
·
Oct 11

Akeso Doses First Patient in Phase III Cadonilimab Perioperative Trial for MSI-H/dMMR Colon Cancer

Reuters
·
Oct 10

Movement Alert|AKESO Rises 4.26% in Regular Trading, ESMO Conference Catalyzes Innovative Drug Valuation

Market Focus
·
Oct 09

Movement Alert|AKESO Intraday Decline 3.02%, Biotechnology Sector Profit-Taking Drags Innovative Drug Stocks

Market Focus
·
Oct 08

Akeso Leaves Share Count Unchanged in September 2026; 10.81 Million Options Outstanding

Bulletin Express
·
Oct 07

Movement Alert|AKESO Falls 3.16% in Regular Trading, Biotech Sector Selloff Dragging Down Innovative Drug Stocks

Market Focus
·
Oct 07

Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts

Stock News
·
Oct 06

Movement Alert|AKESO Rises 3.3% in Regular Trading, Ivonescimab Global Combination Therapy Advances

Market Focus
·
Oct 06

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Akeso (SEHK:9926) Could Be 31% Undervalued As Phase III Trial Hits Key Goals

Simply Wall St.
·
Oct 02

Movement Alert|AKESO Falls 3.59% in Regular Trading, Biotech Sector Broadly Weak as Post-Rally Profit-Taking Continues

Market Focus
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Should Phase III Cancer Trial Win Require Action From Akeso Stock Investors?

Simply Wall St.
·
Sep 30

Daiwa: Akeso's Global Partner Summit Secures AstraZeneca Investment, Boosting Ivonescimab's Global Peak Sales Potential

Stock News
·
Sep 30

Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso

Stock News
·
Sep 30

Movement Alert|AKESO Falls 3.86% in Regular Trading, Profit-Taking After Previous Session Surge of Over 15% on AstraZeneca-Summit Deal

Market Focus
·
Sep 30

Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal

Deep News
·
Sep 29